A simple pill can soon cure diabetes: Scientists

Researchers at Mount Sinai are developing a revolutionary pill using harmine, a DYRK1A inhibitor, to regenerate insulin-producing beta cells in the pancreas. Harmine alone tripled beta cell mass, and combined with a GLP-1 agonist like Ozempic, increased it by 700%. The team discovered that alpha cells could potentially be transformed into beta cells, offering a new source for insulin production.

New pathway explains poor response to bladder cancer immunotherapy

news.medical.net - 19/Mar 02:05

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps...

Vitamin B2 metabolism helps cancer cells resist ferroptosis

news.medical.net - 14/Mar 02:43

A lack of vitamin B2 makes tumour cells more susceptible to a unique form of cell death. This was discovered by researchers at the Rudolf Virchow...

Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks ...

wn.com - 25/Mar 06:34

UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn...

Insulin pills may soon replace daily injections, study shows

knowridge.com - 10:40

Living with diabetes often means dealing with daily insulin injections. For many people, this routine is not only uncomfortable but also emotionally...

Study Finds GLP‑1 Therapy Reduces Heart and Kidney Risks for Type 1 Diabetes Patients

wn.com - 24/Mar 16:59

The results suggest that the five-year risk of major cardiovascular events such as heart attacks and the risk of end-stage kidney disease were reduced...

Preterm Birth Up With Periconceptional GLP-1 Receptor Agonist Exposure for Diabetes

drugs.com - 23/Mar 16:03

MONDAY, March 23, 2026 -- Periconceptional exposure to glucagon-like peptide-1 (GLP-1) receptor agonists is associated with increased odds of preterm...

Perovskite solar cells can be made without expensive cleanrooms

wn.com - 25/Mar 07:12

Swansea University researchers found that perovskite solar cells can tolerate dusty fabrication environments, performing almost as well as those made...

Triple agonist UBT251 showed a mean HbA1c reduction of up to 2.16% after 24 weeks in phase 2 trial in Chinese patients with type 2 diabetes

sloveniatimes.com - 25/Mar 06:16

UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo Nordisk...

GLP-1 drugs cut heart and kidney risks in type 1 diabetes study

news.medical.net - 23/Mar 00:05

In a large target trial emulation of 174,678 people with type 1 diabetes, GLP-1 receptor agonist initiation was associated with lower risks of major...

Weight loss drug Ozempic cuts depression, anxiety, and addiction risk

wn.com - 22/Mar 12:39

GLP-1 medications like semaglutide (Ozempic) may offer...

Rubriques :